-
Mashup Score: 0
The FDA’s ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC lacking HRR mutations.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
Durvalumab added to BCG induction and maintenance improved disease-free survival vs BCG alone in high-risk non–muscle-invasive bladder cancer.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
Adding panitumumab to neoadjuvant FOLFOX cut recurrence risk and improved survival in locally advanced, RAS/BRAF wild-type colon cancer.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
KEYNOTE-B96 showed pembrolizumab-based therapy improved PFS and OS in PD-L1–positive platinum-resistant ovarian cancer.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet
-
Mashup Score: 1
A nurse practitioner gives her advice for managing adverse events during treatment with talquetamab for multiple myeloma.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
CT0596 was well tolerated and showed preliminary efficacy in relapsed/refractory multiple myeloma, early phase 1 data show.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet
-
Mashup Score: 1
Neoadjuvant ribociclib plus endocrine therapy showed pCR rates comparable to chemo in HR-positive, HER2-negative early breast cancer.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
Disitamab vedotin with toripalimab improved PFS and OS over chemo in HER2-expressing metastatic urothelial carcinoma, per phase 3 trial interim analysis.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Ibrutinib/Nivolumab Yields Activity in Relapsed CNS Lymphoma - 8 day(s) ago
Three of 18 patients had remissions lasting over 2 years in a study of ibrutinib plus nivolumab for relapsed/refractory CNS lymphoma.
Source: www.oncnursingnews.comCategories: General Medicine NewsTweet
ODAC Votes Against Talazoparib Combo for Patients With non-HRR mCRPC. Read more below: https://t.co/Veze1cdweY